Compare fund portfolios
See how two funds' portfolios overlap. Enter two tickers:
WDNA vs IBB
Shared holdings
53
WDNA covered by IBB
28.59%
IBB covered by WDNA
28.59%
Coverage = share of one portfolio's weight reproduced by the other (overlapping positions, min weight). Top 50 positions per side shown; = held by both — hover a shared position to highlight it in both columns.
WDNA (March 31, 2026)
| Security | Weight | |
|---|---|---|
| MODERNA INC | 4.53% | |
| JOHNSON&JOHNSON | 3.15% | |
| UNITED THERAPEUTICS CORP DEL | 2.80% | |
| PFIZER INC | 2.73% | |
| LILLY ELI and CO | 2.64% | |
| STOKE THERAPEUTICS INC | 2.52% | |
| NATERA INC | 2.52% | |
| AMGEN INC | 2.34% | |
| TWIST BIOSCIENCE CORP | 2.31% | |
| ASTRAZENECA PLC | 2.28% | |
| STRUCTURE THERAPEUTICS INC ADR | 2.20% | |
| AMICUS THERAPEUTICS INC | 2.19% | |
| BIONTECH SE ADR | 2.09% | |
| IONIS PHARMACEUTICALS INC | 2.06% | |
| GILEAD SCIENCES INC | 1.95% | |
| CRISPR THERAPEUTICS AG | 1.87% | |
| IMMUNOME INC | 1.86% | |
| NOVOZYMES A S | 1.85% | |
| BEAM THERAPEUTICS INC | 1.81% | |
| 10X GENOMICS INC | 1.78% | |
| DARLING INGREDIENTS INC | 1.70% | |
| Novartis AG (Registered) | 1.64% | |
| ROIVANT SCIENCES LTD | 1.60% | |
| KRYSTAL BIOTECH INC | 1.57% | |
| AGIOS PHARMACEUTICALS INC | 1.56% | |
| BUNGE GLOBAL SA | 1.54% | |
| NOVO NORDISK-B | 1.48% | |
| INTELLIA THERAPEUTICS INC | 1.48% | |
| CORTEVA INC | 1.45% | |
| ARROWHEAD PHARMACEUTICALS INC | 1.43% | |
| VERTEX PHARMACEUTICALS INC | 1.36% | |
| REGENXBIO INC | 1.32% | |
| ARCELLX INC | 1.28% | |
| ALLOGENE THERAPEUTICS INC | 1.24% | |
| BRISTOL-MYERS SQUIBB CO | 1.19% | |
| TAKEDA PHARMACEU | 1.16% | |
| REGENERON PHARMACEUTICALS INC | 1.12% | |
| GENMAB A/S -SP ADR DEPOSITARY RECEIPT | 1.10% | |
| VERBIO VEREINI | 1.04% | |
| BIOMARIN PHARMACEUTICAL INC | 1.02% | |
| Bayer Aktiengesellschaft | 1.01% | |
| ARGENX SE SPONSORED ADR | 0.93% | |
| VIKING THERAPEUTICS INC | 0.91% | |
| VERACYTE INC | 0.90% | |
| EDITAS MEDICINE INC | 0.89% | |
| DANAHER CORP | 0.89% | |
| ARCTURUS THERAPEUTICS HOLDINGS INC | 0.85% | |
| ABSCI CORP | 0.84% | |
| IOVANCE BIOTHERAPEUTICS INC | 0.82% | |
| TEMPUS AI INC-A | 0.78% |
IBB (March 31, 2026)
| Security | Weight | |
|---|---|---|
| BlackRock Cash Funds: Institutional, SL Agency Shares | 8.81% | |
| GILEAD SCIENCES INC | 7.06% | |
| AMGEN INC | 6.84% | |
| VERTEX PHARMACEUTICALS INC | 6.79% | |
| REGENERON PHARMACEUTICALS INC | 6.58% | |
| ALNYLAM PHARMACEUTICALS INC | 3.64% | |
| INSMED INC | 2.91% | |
| ARGENX SE SPONSORED ADR | 2.80% | |
| BIOGEN INC | 2.25% | |
| NATERA INC | 2.20% | |
| UNITED THERAPEUTICS CORP DEL | 2.10% | |
| BEONE MEDICINES LTD ADR | 1.76% | |
| INCYTE CORP | 1.55% | |
| MODERNA INC | 1.54% | |
| ILLUMINA INC | 1.53% | |
| REVOLUTION MEDICINES INC | 1.40% | |
| ROIVANT SCIENCES LTD | 1.13% | |
| NEUROCRINE BIOSCIENCES INC | 1.08% | |
| GENMAB A/S -SP ADR DEPOSITARY RECEIPT | 1.07% | |
| BRIDGEBIO PHARMA INC | 1.03% | |
| IONIS PHARMACEUTICALS INC | 1.02% | |
| MEDPACE HOLDINGS INC | 0.92% | |
| MADRIGAL PHARMACEUTICALS INC | 0.91% | |
| EXELIXIS INC | 0.90% | |
| BIOMARIN PHARMACEUTICAL INC | 0.90% | |
| Ascendis Pharma A/S | 0.87% | |
| PRAXIS PRECISION MEDICINES INC | 0.71% | |
| CHARLES RIVER LABS INTL INC | 0.70% | |
| ARROWHEAD PHARMACEUTICALS INC | 0.69% | |
| VAXCYTE INC | 0.68% | |
| BIO-TECHNE CORP | 0.68% | |
| CYTOKINETICS INC | 0.66% | |
| HALOZYME THERAPEUTICS INC | 0.63% | |
| AXSOME THERAPEUTICS INC | 0.61% | |
| BIONTECH SE ADR | 0.60% | |
| KRYSTAL BIOTECH INC | 0.55% | |
| PROTAGONIST THERAPEUTICS INC | 0.53% | |
| REPLIGEN CORP | 0.52% | |
| KYMERA THERAPEUTICS INC | 0.49% | |
| ALKERMES PLC | 0.48% | |
| RHYTHM PHARMACEUTICALS INC | 0.46% | |
| Abivax SA SPONSORED ADS | 0.46% | |
| PTC THERAPEUTICS INC | 0.45% | |
| COGENT BIOSCIENCES INC | 0.44% | |
| ARCELLX INC | 0.43% | |
| TERNS PHARMACEUTICALS INC | 0.42% | |
| NUVALENT INC-A | 0.41% | |
| MIRUM PHARMACEUTICALS INC | 0.41% | |
| TEMPUS AI INC-A | 0.39% | |
| XENON PHARMACEUTICALS INC | 0.39% |
Machine-readable: JSON · Markdown. Programmatic access via the agent surface.